How should I use Rubraca(Rucaparib)?

The dosage of Rubraca varies depending on the patient's response and clinical condition.

Dosage of Rubraca

Rubraca is administered orally, with the standard recommended dose being 600 mg (two 300 mg tablets) twice daily. This dosage is suitable for patients who meet the criteria for maintenance treatment of BRCA mutation-positive ovarian cancer.

It is important for clinicians to assess renal function, as dose adjustments may be required for patients with moderate to severe renal impairment. Specific guidelines regarding dosage adjustments for other indications or patient populations are not specified in the description.

Related Columns

Rucaparib(Rubraca)

Adult patients with BRCA-mutated advanced ovarian cancer who have previously...

WeChat Scan
Free Inquiry

Guidelines for the administration of Rucaparib

Rucaparib is a targeted therapy drug that targets specific gene mutations and is widely used in the treatment of ovarian and prostate cancer. This article will systematically sort out the core in...

How to use Rucaparib?

Rucaparib is an orally active and potent inhibitor of polyadenosine diphosphate ribose polymerase (PARP). This drug is known for its potent inhibition of PARP1, with a Ki value of 1.4 nM for PARP...

Guide to the use of Rucaparib

Rucaparib is a targeted therapy for tumors with specific gene mutations, mainly for patients with BRCA mutation-related ovarian and prostate cancer.Guide to the use of RucaparibThe drug is a PARP...